

EDEN No	Age at Sampling	Time from onset (Y)	Gender	Ethnicity	Sample Serostatus		Diagnosis	2006 Criteria for NMO						Fulfill NMO Criteria	
					Sent as	Final Serology		ON		Myelitis		Imaging			Serology
					Pos/Neg	Designation		R	M	R	M	LETM	Non-MS Brain		AQP4 Pos
1	46	10	F	Caucasian	n	n	Control-RRMS								
2	37	2	F	Caucasian	n	n	Control-RRMS								
3	36	5	F	Caucasian	n	n	Control-RRMS								
4	46	3	F	Suriname	n	n	Control-RRMS								
5	43	9	M	Caucasian	n	n	Control-RRMS								
6	43	14	F	Caucasian	n	n	Control-RRMS								
7	35	16	M	Caucasian	n	n	Control-MS								
8	52	2	F	Caucasian	n	n	Control-RRMS								
9	53	13	M	Caucasian	positive	positive	NMO	n	Y	Y	n	Y	Y	Y	Y
10	34	0	M	Caucasian	n	n	NMO	n	Y	n	Y	Y	Y	n	Y
11	34	0	F	Caucasian	n	n	TM	n	n	n	Y	Y	Y	n	n
12	43	1	F	Caucasian	positive	positive	NMO	n	Y	Y	n	Y	Y	Y	Y
13	49	3	F	Caucasian	positive	positive	TM	n	n	n	Y	Y	Y	Y	n
14	42	11	F	Caucasian	positive	positive	NMO	Y	n	Y	n	Y	Y	Y	Y
15	59	1	F	Caucasian	positive	positive	NMO	Y	n	n	Y	Y	Y	Y	Y
16	47	1	F	Caucasian	n	n	NMO	Y	n	Y	n	Y	Y	n	Y
17	33	6	M	Dutch	n	n	ON+TM	Y	n	Y	n	n	Y	n	n
18	45	15	M	Dutch	n	n	Control-RRMS								
19	39	1	F	Dutch	n	n	NMO	Y	n	Y	n	Y	Y	n	Y
20	52	11	M	Dutch	n	n	TM	n	n	Y	n	n	Y	n	n
21	69	unknown	M	Dutch	n	n	Control-PPMS								
22	24	0	F	Dutch	n	n	Control-RRMS								
23	43	4	F	Dutch	n	n	NMO	Y	n	n	Y	Y	Y	n	Y
24	45	0	F	Dutch	n	n	NMO	n	Y	n	Y	Y	Y	n	Y
25	18	7	F	Cape Verdean	n	n	Control-RRMS								
26	67	1	F	Dutch	positive	positive	NMO	n	Y	n	Y	Y	Y	Y	Y
27	45	2	F	Dutch	positive	n	TM	n	n	n	Y	Y	Y	n	n
28	31	9	F	Unknown	positive	positive	NMO	n	Y	Y	n	Y	Y	Y	Y
29	57	8	F	Dutch	positive	positive	NMO	n	Y	n	Y	Y	Y	Y	Y
30	42	1	M	Dutch	n	n	TM	n	n	Y	n	n (2.5	Y	n	n
31	44	30	M	Dutch	n	n	ON+TM	n	Y	n	Y	n (but	Y	n	n
32	21	2	M	Mixed (mother Moroccan/ father	n	n	Control-ADEM								
33	18	1	M	Dutch	n	n	ON	Y	n	n	n	n	Y	n	n
34	35	8	F	Cape Verdean	positive	positive	NMO*	Y	n	Y	n	n	Y	Y	Y
35	29	8	F	Thailand	positive	positive	NMO	n	Y	Y	n	Y	Y	Y	Y
36	52	2	F	Dutch	positive	positive	TM	n	n	n	Y	n (2	Y	Y	n
37	54	1	F	Ghana	positive	positive	NMO	n	Y	Y	n	Y	Y	Y	Y
38	20	1	F	Suriname	positive	positive	ON	Y	n	n	n	n	Y	Y	n

EDEN No	Age at Sampling	Time from onset (Y)	Gender	Ethnicity	Sample Serostatus		Diagnosis	2006 Criteria for NMO						Fulfill NMO Criteria	
					Sent as	Final Serology		ON		Myelitis		Imaging			Serology
					Pos/Neg	Designation		R	M	R	M	LETM	Non-MS Brain		AQP4 Pos
78	19	7	M		n	n	Control-RRMS								
79	42	0	M		n	n	Control-RRMS								
80	40	5	F		n	n	Control-RRMS								
81	34	1	F		n	n	Control-RRMS								
82	33	1	F		n	n	Control-RRMS								
83	51	16	F		n	n	Control-RRMS								
84	29	1	M		n	n	Control-RRMS								
85		0		Caucasian	n	n	Control-RRMS								
86		0		Caucasian	n	n	Control-RRMS								
87	57	unknown	f	Caucasian	positive	positive	NMO*	n	Y	Y	n	Y	n	Y	Y
88	36	13	M	Danish	n	n	NMO	n	Y	n	Y	Y	Y	n	Y
89	21	5	F	Danish	positive	positive	NMO	Y	n	Y	n	Y	Y	Y	Y
90	46	7	M	Danish	negative but	n	NMO	n	Y	Y	n	Y	Y	n	Y
91	30	0	F	Danish	n	n	NMO	n	Y	Y	n	Y	Y	n	Y
92	40	24	F	Danish	negative but	n	NMO	n	Y	Y	n	Y	Y	n	Y
93	52	11	F	Danish	positive	n	NMO	n	Y	Y	n	Y	Y	n	Y
94	36	4	F	Danish	positive	positive	NMO	Y	n	n	Y	Y	Y	Y	Y
95		0			n	n	Control - headache								
96		0			n	n	Control - headache								
97		0			n	n	Control - headache								
98		0			n	n	Control - headache								
99		0			n	n	Control - headache								
100		0			n	n	Control - headache								
101		0			n	n	Control - headache								
102		0			n	n	Control - headache								
103		0			n	n	Control - headache								
104		0			n	n	Control - headache								
105		0			n	n	Control - headache								
106		0			n	n	Control - headache								
107		0			n	n	Control - headache								
108		0			n	n	Control - headache								
109		0			n	n	Control - headache								
110	28	3	F	Caucasian	n	excluded	MG								
111	31	0	F	Asian	n	n	TM	n	n	n	Y	Y	Y	n	n
112	43	2	F	Caucasian	n	n	Control-MS								
113	62	9	F	Caucasian	n	n	Control-MS								
114	25	6	M	Afro-Caribbean	positive	positive	NMO	n	Y	Y	n	Y	Y	Y	Y
115	35	3	F	Asian	n	n	NMO	n	Y	n	Y	Y	Y	n	Y
116	69	20	F	Caucasian	positive	positive	TM	n	n	Y	n	Y	Y	Y	n

EDEN No	Age at Sampling	Time from onset (Y)	Gender	Ethnicity	Sample Serostatus		Diagnosis	2006 Criteria for NMO						Fulfill NMO Criteria	
					Sent as	Final Serology		ON		Myelitis		Imaging			Serology
					Pos/Neg	Designation		R	M	R	M	LETM	Non-MS Brain		AQP4 Pos
156	52	2	F	Caucasian	positive	positive	ON	n	Y	n	n	n	Y	Y	n
157	58	0	F	Caucasian	n	n	TM	n	n	n	Y	Y	Y	n	n
158	66	16	M	Caucasian	n	n	NMO	n	Y	Y	n	Y	Y	n	Y
159	36	0	F	Caucasian	n	n	TM	n	n	n	Y	Y	Y	n	n
160	52	2	F	Afro-Caribbean	positive	positive	TM	n	n	n	Y	Y	Y	Y	n
161	51	8	F	Caucasian	positive	positive	ON	n	Y	n	n	n	Y	Y	n
162	31	6	F	Caucasian	positive	n	TM	n	n	Y	n	n	Y	n	n
163	52	4		Asian	n	excluded	MG								
164	40	3	F	Caucasian	positive	positive	TM	n	n	n	Y	Y	n	Y	n
165	68	2	F	Caucasian	positive	positive	TM	n	n	n	Y	Y	Y	Y	n
166	62	20	F	Caucasian	n	excluded	MG								
167	67	1	F	Caucasian	n	n	TM	n	n	Y	n	Y	Y	n	n
168	52	17	M	Caucasian	positive	positive	TM	n	n	Y	n	Y	Y	Y	n
169	47	2	F	Caucasian	n	n	Control-MS								
170		0	F	Caucasian	positive	positive	ON	Y	n	n	n	n	n	Y	n
171		0	F	Caucasian	positive	positive	NMO	n	Y	Y	n	Y	Y	Y	Y
172		0	F	Caucasian	n	n	Control-tumour								
173		0	F	Asian	positive	positive	NMO*	Y	n	Y	n	Y	n	Y	Y
174	29	1	F		n	n	Control-CIS								
175	35	1	F		n	n	Control-CIS								
176		0	F	Caucasian	n	n	Control-Susac								
177		0	F	Caucasian	positive	positive	TM	n	pa	Y	n	Y	not done	Y	n
178		0	F	Caucasian	positive	positive	NMO	Y	n	Y	n	Y	Y	Y	Y
179		0	M	Caucasian	n	n	Control-tumour								
180	75	3	F		positive	positive	NMO	Y	n	Y	n	Y	Y	Y	Y
181	35	0	F		n	n	Control-CIS								
182		0	F	Caucasian	positive	positive	NMO	Y	n	Y	n	Y	Y	Y	Y
183		0	F	Caucasian	positive	positive	TM	n	n	Y	n	Y	Y	Y	n
184		0	F	Caucasian	positive	positive	NMO	n	Y	n	Y	Y	Y	Y	Y
185		0	M	Caucasian	n	n	NMO	Y	n	Y	n	Y	Y	n	Y
186	42	2	F		positive	positive	TM	n	n	n	Y	Y	Y	Y	n
187	66	5	F		positive	positive	TM	n	n	Y	n	Y	Y	Y	n
188		0	F	Caucasian	positive	positive	NMO	n	Y	n	Y	Y	Y	Y	Y
189		0	F	Caucasian	n	n	Control-CTD								
190		0	F	Caucasian	positive	n	TM	n	n	Y	n	Y	Y	n	n
191		0	F	Caucasian	positive	positive	TM	n	n	Y	n	Y	Y	Y	n
192	38	0	M		n	n	Control-CIS								
193	25	5	F		positive	positive	NMO	n	Y	n	Y	Y	Y	Y	Y

EDEN No	Clinical Details				ASSAY												
	Brain or [Y/N]	Coexisting AID? [Y/N] Disorder		Disease activity	No. 1 CBA	No. 2 CBA	No. 3 CBA	No. 4 CBA-EI	No. 5 CBA-EI	No. 6 CBA-EI	No. 7 CBA-EO	No. 8 CBA-EO	No. 9 CBA-EO	No. 10 CBA-EO	No. 11 CBA-EO	No. 12 CBA-EO	No. 13 CBA-EO
1																	
2																	
3																	
4																	
5																	
6																	
7																	
8																	
9	n	Y	Sjögren-	Rel	++++	++++	++++	+++	++	++	+	++++	++++	+++	++	+++	++
10	n	n		Rel													
11	Y	n		Rel												++	
12	n	Y	SLE	Rem	+++	++++	++++	+++	+++	++	++++	++++	++++	+++	++	++++	+++
13	n	n		Rem	++	+++	++++	++	++	++	++	+++	+++	++	+	+++	+++
14	n	n		Rel	++++	+++	++++	+++	++++	+++	++++	++++	++++	+++	+++	+++	+++
15	n	n		Rem	++++	++++	++++	+++	++	++	++	++++	+++	+++	++	+++	+++
16	n	Y	Hashimot	Rem													
17	n	n															
18																	
19	n	Y	Rheumato	Rem													
20	n	n		Rem													
21																	
22																	
23	n	n		Rem													
24	n	n		Rem													
25																	
26	n	n	Positive	Rem	++	+++	+++	++		+	+	+	+++	++	+	++	+
27	n	n		Rem												+	
28	n	n		Rel	++++	++++	++++	++	++	++	++	+++	++++	++	+++	+++	+++
29	n	Y	Myastheni	Rem	++	++	+++	++	+	+	+	+	++		+	+	+
30	n	n		Rem													
31	n	n		Rem													
32																	
33	n	n		Rel												+	
34	Y	n		Rem	++++	++++	++++	+++	+++	++	+++	++++	++++	+++	+++	+++	++++
35	Y	n		Rem	+++	++++	++++	++	++	++	++++	+++	+++	++	+	+++	+++
36	n	n		Rem	++	++++	++++	++	++	++	++	+++	+++	++	++	+++	+++
37	n	n		Rel	++	++	++++	+++	++	++	++	++++	+++	++	+	+++	+++
38	n	n		Rem	++	++	+++	++	+	+	+	+	++			+	

EDEN No	Clinical Details				ASSAY												
	Brain or [Y/N]	Coexisting AID? [Y/N] Disorder		Disease activity	No. 1 CBA	No. 2 CBA	No. 3 CBA	No. 4 CBA-EI	No. 5 CBA-EI	No. 6 CBA-EI	No. 7 CBA-EI	No. 8 CBA-EI	No. 9 CBA-EI	No. 10 CBA-EI	No. 11 CBA-EI	No. 12 CBA-EI	No. 13 CBA-EI
78																	
79																	
80																	
81																	
82																	
83																	
84																	
85																	
86																	
87	n	n	n	Rem	+++	++++	++++	+++	++	++	++	++++	+++	++	++	+++	+
88	Y	n		Rem													
89	n	n		Rem	+	++	++	+	+		+	++					
90	Y	n		Rem													
91	Y	n		Rel													
92	Y	n		Rem													
93	n	n		Rem												++	
94	n	n			++++	++++	++++	++++	+++	+++	+++	++++	++++	++	++++	+++	+++
95																	
96																	
97																	
98																	
99																	
100																	
101																	
102																	
103																	
104																	
105																	
106																	
107																	
108																	
109																	
110																	
111	n	n		Rem													
112																+++	
113																+++	
114	n	Y	SLE	Rem	+++	+++	++++	+++	+++	+++	++++	++++	++++	+++	+++	++++	+++
115	n	n		Rem													
116	n	Y	MG	Rem	++	+++	+++	++	++	++	+	++	+++	++	++	+++	+

EDEN No	Clinical Details				ASSAY												
	Brain or [Y/N]	Coexisting AID? [Y/N]	Disorder	Disease activity	No. 1 CBA	No. 2 CBA	No. 3 CBA	No. 4 CBA-EI	No. 5 CBA-EI	No. 6 CBA-EI	No. 7 CBA-EO	No. 8 CBA-EO	No. 9 CBA-EO	No. 10 CBA-EO	No. 11 CBA-EO	No. 12 CBA-EO	No. 13 CBA-EO
156	n	Y	hypothyro	Rem	+++	++++	++++	+++	+++	+++	+++	++++	++++	++	+++	+++	+++
157	n	n		Rem													
158	n	n		Rem													
159	Y	n		Rel													
160	Y	n		Rem	+++	+++	++++	+++	++	++	++	+++	++++	+++	++	++++	+++
161	n	Y	MG with	Rem	++	+++	+++	++	++	++	+	+++	++	++	+	+++	+
162	n	n		Rem		+	+										
163							+										
164	Y	n		Rem	+	+	++				+	+					
165	n	n		Rem	+	+	+										
166					+		++										+
167	n	n		Rel													
168	n	n		Rem	+	+	++										
169																	
170					+	+	+										++
171					++++	++++	++++	++++	++++	+++	++++	++++	++++	+++	++++	++++	+++
172																	+++
173					++++	++++	++++	++++	++++	++++	+++	++++	++++	++++	++++	+++	++++
174																	
175																	
176																	
177					++	+++	+++	++	++	++	++	++	+++	++	+	+++	++
178					++	+++	++	++	++	++	+++	+++	+++	++	+	+++	+++
179																	
180	n	Y	Myastheni	Rem	+++	++++	++++	++	++	++	+++	++++	++	+	+	++	+++
181																	
182					+++	++++	++++	++	++	++	++	+++	+++	++	++	++	+++
183					+++	+++	++++	++	++	++	+	++	+++	++	+	++	++
184					++	++++	++++	++	++	++	+++	++++	++++	++	++	+++	+++
185																	
186	n	n		Rem	++++	++++	++++	+++	+++	+++	+++	++++	++++	++	+++	+++	++++
187	Y	Y	Myastheni	Rem	++	++	++	++	++	+	+	+	++	+		++	
188					++	++	+	++	+	+	+	++	++	+	+	+	sult, hemc
189																	
190																	
191					++	+++	++	++	+	+		+	+	+		+	
192																	
193	n	n		Rem	+++	++++	++++	++	++	++	++	+++	+++	++	++	++	+++

ASSAY													Positive in
EDEN No	No. 14 FACS	No. 14 Raw Data	No. 15 FACS	No. 15 Raw Data	No. 16 FACS	No. 16 Raw Data	No. 17 FACS	No. 17 Raw Data	No. 18 TBA-IHC	No. 19 TBA-IIF	No. 20 TBA-IIF	No. 21 ELISA	No. of Assays
1		133	+	368.5		-0.02		≤0					1
2		370		20.5		0.04		≤0					0
3		258	+	732		-0.15		≤0					1
4		-20		-50		-0.1		≤0					0
5		-29		37.5		-0.01		≤0					0
6		22		-109.5		-0.09		≤0					0
7		25		-67.5		-0.23		≤0					0
8		23		-115		0.06		≤0					0
9	++++	150849	++++	7547.5	+++	15.78	++++	1265.9	++++	++	++	++++	21
10		41		94		-0.05		≤0					0
11		26		-117.5		0.19		5.29					1
12	++++	179151	+++	3734	++	6.9	++	115.58	++++	++		++++	20
13	++++	147048	+++	3628.5	++	4.05	+	42.53	+++	+		+++	20
14	+++	113211	++++	7228	++++	16.93	++++	588.76	++++	++++	++++	++++	21
15	++++	132378	++++	6929.5	+++	10.37	+++	906.01	++++	++	++	++++	21
16		28		-14		-0.08		≤0					0
17		44		-59		-0.04		≤0					0
18		-24		314.5		0.06		2.08					0
19		220		-51.5		-0.03	+	66.39					1
20		12		-18		-0.02		14.86					0
21		60		2		-0.04		≤0					0
22		245		-70.5		-0.05		≤0					0
23		83		-96		-0.25		18.99					0
24		334	+	412.5		-0.06		18.99					1
25		245		-6		-0.02		15.1					0
26	+++	65973	++	1219	+	1.11		21.51	++			+	17
27		374	+	915		0.03		14.05					2
28	++++	133577	++++	7713	++++	20.78	++	159.38	+++	+++	+	+++	21
29	+++	109823	++	661.5	+	1.4	+	41.01	++	+	+		19
30		96		-62		-0.03		17.04					0
31		29		19		-0.01		20.41					0
32		-72		-25.5		-0.02		13.21					0
33		-25		-19.5		-0.01		≤0					1
34	+++	124755	+++	4112.5	+++	9.12	+	61.5	+++	+++	+	++++	21
35	+++	110352	+++	3411.5	++	6.41	++	470.17	++++	++	++	++++	21
36	+++	112452	+++	2349.5	++	4.75	++	333.7	+++	++	+++	++	21
37	++	46387	++	1299.5	+	1.57		10.73	++++	++	+++	+++	20
38	++	38123	+	494		0.66		28.26	+++	+	++	+	16

ASSAY													Positive in
EDEN No	No. 14 FACS	No. 14 Raw Data	No. 15 FACS	No. 15 Raw Data	No. 16 FACS	No. 16 Raw Data	No. 17 FACS	No. 17 Raw Data	No. 18 TBA-IHC	No. 19 TBA-IIF	No. 20 TBA-IIF	No. 21 ELISA	No. of Assays
39	+++	122621	+++	3640	+++	13.94	++	109.37	+++	+++	+++	++++	21
40	+	2278		-43		0.1		≤0					3
41	++++	133714	+++	3936.5	++	5.19		4.03	+++	+		++	19
42	++++	150307	+++	2782.5	+++	8.24		7.55	+++	+	+	++++	20
43	+++	112828	++++	7083.5	++++	20.53	++++	854.04	++++	++		++++	20
44	+++	102152	++++	6751.5	++++	20.47	++++	1555.1	+++	++++	++	+	21
45		178		-78.5		0.05		≤0					2
46	++	43278	++++	5572	++++	19.03	+++	268.6	++++	++		++++	20
47		38	+	283		0.11		≤0					1
48	++	54747	++	833.5	+	1.11		≤0	++			+	15
49	+++	120074	+++	2732	++	4.74		23.59	+++	++	++	+++	20
50	++++	146559	++++	4458.5	++++	20.07	+++	276.11	++++	+++	+++	++++	21
51	++++	155149	++++	9750.5	++++	16.22	++	143.85	++++	+++	+	+++	21
52	++++	144059	++++	13413.5	++++	22.49	+++	712.26	+++	++	+	++++	21
53	++++	137911	++++	8494.5	++++	16.31	++	260.71	+++		++	++++	20
54	++++	150933	++++	8977	++++	20.23	+++	413.93	+++	+++	+++	++++	21
55		-1718		9688		-0.04		26.9					0
56		-1339		9902		-0.04		≤0					0
57		-1623		7999		-0.04		15.1					0
58	+++	110933	+++	4398.5	++	4.3	+	39.78	++++	+	+++	+++	21
59	++	76439	++	2490	+	2.48		24.64	+++	+			18
60		169		-164.5		0.02		4.39			++		1
61	++++	147438	+++	6283	++	5.34	+	89.42	+++	++		++	20
62	+	25267	++	1291.5		-0.06		≤0	+	+			12
63	++++	156174	+++	4925	++	7.15	+	56.6	++	++	+++	+	21
64	++	39635		9		0		≤0					1
65	+++	128216	+++	5781.5	++	5.76		47	++	++	+	+++	20
66	+	10209	++	1987		-0.03		≤0		+		+++	16
67	+++	113153	+++	5372	+++	8.1	+	81.93	+++			+++	19
68	+++	98505	++++	22530.5	++++	23.76	+++	662.63	++++	++		+++	20
69		279		282		-0.03		≤0					1
70		68		-53.5		0.02		9.44					1
71		60		-209.5		0.02		≤0					1
72	++++	141981	++++	9888.5	++++	24.05	++	352.82	++++	+++	+++	+++	21
73		73		91		0.02		≤0					0
74		43		-141.5		0.03		≤0					0
75		83		-129		0.03		≤0	+				2
76	+	628		59		0.01		5.37					2
77		111		-98.5		0.03		≤0					0

ASSAY													Positive in
EDEN No	No. 14 FACS	No. 14 Raw Data	No. 15 FACS	No. 15 Raw Data	No. 16 FACS	No. 16 Raw Data	No. 17 FACS	No. 17 Raw Data	No. 18 TBA-IHC	No. 19 TBA-IIF	No. 20 TBA-IIF	No. 21 ELISA	No. of Assays
78		52		-123		-0.02		≤0					0
79		58		-112		0		11.72					0
80		69		-79.5		0		≤0					0
81		-196		59		0.09	+	84.45					1
82		15		-66.5		0.01		≤0					0
83		250		-121		0.02		4.73					0
84		17		-226.5		0.01		≤0					0
85		-1893		10874.5		0.02		21.17					0
86		-1715		10153		0.02		11.03					0
87	+++	117769	+++	7519.5	++	5.16	++	508.34	+++	++	+	+	21
88		23		-43		-0.01		11.66					0
89	++	18206	+	395.5		0.31		4.77	++	+			11
90		-30		-99.5		0.02		≤0					0
91		-7	++	928.5		-0.32		≤0					1
92		40		203.5		-0.2		≤0					0
93		-142		42.5		-0.34	+	69.71			+		3
94	+++	106723	++++	15630.5	++++	18.23	++++	678.65	++++	+++	++	++++	21
95		62		-28		-0.04		≤0					0
96		-32		-66.5		-0.03		4.48					0
97		63		-49.5		-0.03		≤0					0
98	+	1219		25.5		-0.19		≤0					1
99		-49		-68		-0.2	+	60.16					1
100		-73		7.5		-0.09		1.23					0
101		8		-29.5		-0.03		21.33					0
102		93		-12		-0.05		25.03					0
103		59		10		-0.07	+	65.91					1
104		194		-7.5		-0.25		≤0					0
105		31		-62.5		0.01		17.04					0
106		26		-24.5		0		3.69			++		1
107		26		-101		0.01		4.75					0
108		20		-13.5		-0.04		≤0			++		1
109		-114		134.5		-0.07		13.54					0
110		42		-28		-0.02		35.09					0
111		-203		9.5		-0.06		≤0					0
112		103		-49.5		0.01		13.85					1
113		51		-44.5		0.01		≤0					1
114	+++	107303	++++	25110	+++	15.23	++++	1159.9	+++	++	++	+++	21
115		35		13		-0.02		43.58					0
116	+++	74979	++	1713.5		0.65		6.14	+++	+	+	+	19

ASSAY													Positive in
EDEN No	No. 14 FACS	No. 14 Raw Data	No. 15 FACS	No. 15 Raw Data	No. 16 FACS	No. 16 Raw Data	No. 17 FACS	No. 17 Raw Data	No. 18 TBA-IHC	No. 19 TBA-IIF	No. 20 TBA-IIF	No. 21 ELISA	No. of Assays
117		32		-72		0.04		6.72					1
118		-15		-24.5		-0.02		4.6	++				4
119	++	15481		-177		0.02		≤0					2
120	+++	107110	++++	11260	++	7.48	+	110.4	+++	++	+++	++	21
121		33		-27.5		-0.02		26.88					0
122		52		-20		0		8.88					0
123		36		-46.5		-0.01		18.46					0
124		49		-51.5		0.02		10.15					0
125		-68		-27		-0.04		≤0					0
126		-88		430		-0.09		16.56					0
127		-41		163.5		-0.05		20.16					0
128		-3		22.5		0.03		42.04					0
129		23		43.5		-0.17	+	140.27					1
130		25	+	530		-0.17		72.83					2
131		-18		-30.5		-0.02		69.71					0
132		65		-12.5		-0.06		43.58					0
133		-50		14.5		-0.04		≤0					0
134		13		3		-0.01		0.88				+	1
135		-20		-131.5		0.02		3.98					0
136	++	26420	++++	10850	++	4.78	+	172.53	++++	+		+++	20
137		111		-17.5		-0.02		37.72					1
138	+++	127325	++++	9753	+++	8.82	++	219.52	+++	++		+	19
139	+++	101996	++++	13060	+++	13.12	++	365.79	++++	++	+	++++	21
140		111		32		-0.08		8.91					0
141	+++	80627	++	2314	+	1.05	+	45.35	++	+		+++	19
142		89		-65.5		0.09	++	149.99	+				4
143		36		11		0.04		17.01					0
144		15		-65.5		0.04		15.55					1
145		-420		9.5		0.02		≤0					0
146		29		14		0.05		27.21					0
147		19		-62.5		-0.12	++	278.61					1
148		-5		18		0.06		65.36					0
149		42		158		0.09		44.34					0
150		27		-71		0.04	+	56.35					1
151		225		29.5		0.05		60.8					0
152		-298		103		0.01	++	180.62					1
153		224		96.5		0.07		71.28				+++	1
154		77		7.5		0.04		9.21					0
155		87		-140.5		0.05	+	172.64					2

ASSAY													Positive in
EDEN No	No. 14 FACS	No. 14 Raw Data	No. 15 FACS	No. 15 Raw Data	No. 16 FACS	No. 16 Raw Data	No. 17 FACS	No. 17 Raw Data	No. 18 TBA-IHC	No. 19 TBA-IIF	No. 20 TBA-IIF	No. 21 ELISA	No. of Assays
156	+++	136266	++++	53356.5	+++	13.09	++	409.85	+++	+++		+++	20
157		20	+	299.5		0.06		≤0					1
158		129		-54		-0.97		≤0					0
159		19		-86.5		0.04	+	120.2					1
160	+++	121441	++++	29106.5	+++	11.84	++	172.31	+++	++		++++	20
161	+++	79950	+++	7682	+	2.87	+	133.9	++	+		+	20
162		74	+	271.5		-0.08		≤0					3
163		662	+	586		-0.04		11.97	+				3
164	++	15742	+	573.5		0.08		≤0	++				8
165	+	9435		-28.5		0.06		5.29	+				5
166	+	7145	+	573		0.06		≤0	++				6
167		-40		-45.5		-0.02		≤0					0
168	++	10022	+	397		0.14		≤0	+				6
169		1		-88		-0.02		≤0					0
170	++	9929		96.5		0.04		≤0	+				6
171	+++	118563	++++	40531.5	++++	40.43	+++	1160.4	++++	+++		++++	20
172		66		-171		0.01		≤0					1
173	+++	87667	++++	48391	++++	39.18	++++	1269.9	++++	+++		+++	20
174		285		-132.5		0		≤0					0
175		143		-86		0		≤0					0
176		114		21.5		-0.01		2.31					0
177	++	60659	+++	8955	++	6.82	+	75.06	+	+			19
178	++	53244	+++	3125	+	1.24		17.66	+	++		+	19
179		-79		-88		0		≤0					0
180	+++	86461	++++	31420.5	+++	13.95	+++	932.73	+++	+			19
181		385		-136.5		0.06		≤0					0
182	+++	122437	++++	13072.5	++	4.68	++	418.93	++++	++	+	+++	21
183	+++	75688	++++	13300.5	++	4.15	++	241.1	++++	++	++++	+	21
184	++	48095	++++	15793	++	6.45	+++	533.69	++++	+		++++	20
185	++	31414		-178.5		0.05		≤0					1
186	+++	118640	++++	33070	++++	16.01	++++	1195.1	++++	+++	+++	++++	21
187	++	12932	+	818.5		0.4		18.62	+	+		+	16
188	++	59940	+++	10915.5	++	4.19	++	174.13	+			+++	18
189		497		210		-0.31		≤0				+	1
190	+	2043		104		0.31		≤0				+	2
191	++	31248	++	2177		0.72		28.82	+		++		14
192	+	665		-51.5		0.06		≤0					1
193	+++	91785	++++	19895.5	+++	8.93	+++	733.9	+++	+++	+	+++	21